BriaCell and BriaPro Unveil TILsRx Platform to Advance Next-Generation Multivalent Immunotherapies for Cancer

BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...

July 30, 2025 | Wednesday | News
Zevra Therapeutics Submits MAA to EMA for Arimoclomol (MIPLYFFA®) in Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare ...

July 29, 2025 | Tuesday | News
Can-Fite’s Piclidenoson Shows Promise in Preclinical Vascular Dementia Study Led by UCLA Researchers

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule dr...

July 29, 2025 | Tuesday | News
Bio Usawa and DEK Forge Strategic Alliance to Deliver Monoclonal Antibody Therapies Across West Africa

Bio Usawa, a pioneering private biotechnology company committed to developing and manufacturing affordable, high‑quality monoclonal antibody therapies ...

July 29, 2025 | Tuesday | News
CORXEL Submits NDA for LENZ Therapeutics’ LNZ100 in China, Marking First Global Regulatory Filing for Aceclidine-Based Eye Drop for Presbyopia

LENZ Therapeutics, Inc. a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidin...

July 29, 2025 | Tuesday | News
POP Biotechnologies and CEPI Join Forces to Fast-Track Pandemic-Ready Vaccines with Next-Gen SNAP™ Platform

POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...

July 28, 2025 | Monday | News
Matchpoint Therapeutics Secures Major Partnership with Novartis for Precision Covalent Inhibitor Development

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option ex...

July 25, 2025 | Friday | News
4TEEN4 Pharmaceuticals Doses First Patient in PROCARD1 Trial for Groundbreaking Shock Therapy

4TEEN4 Pharmaceuticals GmbH  announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal anti...

July 25, 2025 | Friday | News
AscellaHealth Boosts Specialty Pharma Services to Help Manufacturers Navigate Market Shocks

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces service and infrastructure ...

July 24, 2025 | Thursday | News
Sygnature Discovery Doubles High-Throughput Chemistry Capacity with £1M Investment

  Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...

July 24, 2025 | Thursday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News
New CEO Dr Michael Grosse Charts Confident Course for Sartorius, Backed by Pharma-Focused Expansion

Group sales revenue up 6.1 percent in the first six months As expected, continued positive trend in recurring business with consumables Bioproce...

July 22, 2025 | Tuesday | Company results
Moderna Halts Plan for Japan mRNA API Facility Amid Market Shifts, Completes Enzymatics R&D Site at Shonan iPark

Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefectu...

July 22, 2025 | Tuesday | News
Longeveron Licenses Breakthrough Stem Cell Patent to Expand Cardiac Regenerative Pipeline

 Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, ra...

July 22, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close